DCM
ACOR

Delpha Capital Management’s Acorda Therapeutics ACOR Stock Holding History

Delpha Capital Management’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-23
Closed -$59K – 1361
2017
Q4 		$59K Buy
+23
New +$65.4K 0.06% 250

Other funds holding ACOR

SCM
Scopia Capital Management New York $112M AUM 48.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
HEC
Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Delpha Capital Management's ACOR Position: Q1 2018 in Review

Delpha Capital Management sold out of Acorda Therapeutics (ACOR) in Q1 2018, closing a stake of 23 shares — an estimated $59K sold.

Delpha Capital Management first reported a position in ACOR in Q4 2017 and held it in 1 quarter. The position peaked at $59K in Q4 2017. 162 funds tracked by Wall St. Rank hold ACOR as of Q1 2018.

  • Delpha Capital Management reported no remaining Acorda Therapeutics position as of Q1 2018 after selling out during the quarter.
  • Delpha Capital Management sold 23 Acorda Therapeutics shares in Q1 2018, an estimated $59K.
  • Delpha Capital Management first reported a position in Acorda Therapeutics in Q4 2017 and held it in 1 quarter.
  • Delpha Capital Management's Acorda Therapeutics position peaked at $59K in Q4 2017.
  • 162 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q1 2018.

Based on Delpha Capital Management's 13F filing for Q1 2018, filed 11 May 2018.